Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells trained to fight advanced throat cancer in new trial

NCT ID NCT05261750

Disease control Sponsor: PT. Prodia Stem Cell Indonesia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a personalized immune cell therapy (dendritic cells) is safe and can help control advanced nasopharyngeal cancer. The treatment uses the patient's own immune cells and donor cell secretions to boost the body's cancer fight. The study involves 15 adults whose cancer did not fully respond to standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who tested positive EBV and confirmed suffering advanced nasopharyngeal cancer * Patients who have partial response or stable disease or progressive disease after performed standard therapy (radiology or chemoradiation) based on RECIST * Did not take traditional medicine in the last 2 months. * Patients can understand the nature of the study and willing to sign informed consent * Patients who received standard medical (radiology or chemoradiation) up to one additional therapy in the last 1 month. Exclusion Criteria: * Patients who are pregnant, planning to pregnant, or breastfeeding * Patients assessed to require chemoradiation during this study * Patients who get complete score after undergo standard therapy (radiology or chemoradiation) based on the RECIST * Patients who have autoimun reaction, eczema, allergy or allergy history, and anaphylaxis * Patients who have creatinin clearance result \<40 ml/min, bilirubin serum \>1.5x above normal, SGPT-SGOT \>5x above normal * Patients on immunosuppressive medications, such as corticosteroids * Patients who undergo Major thoracic or abdominal operation * Patients on high medical risk condition due to uncontrolled infection * Patients who diagnosed positive of Hepatitis B, Hepatitis C or Human Immunodeificiency virus (HIV) * Patients who have concurrent congestive heart failure history and other heart disease * Patients who have health conditions assessed by the doctor in charge cannot be included in this clinical trial * Patients who refuse or did not participate in part or all of the research process

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced nasopharyngeal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal cancer

Contacts and locations

Locations

  • PT Prodia StemCell Indonesia

    Jakarta, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.